Chunghwa Chemical Synthesis & Biotech Co.,Ltd. announced that in terms of the preliminary clinical report of Remdesivir showing promising result towards to the treatment of COVID-19 patients with severe symptoms, CCSB (Chunghwa Chemical Synthesis & Biotech Co. Ltd.), one of the biggest API manufactures in Taiwan, announced on Apr. 15th that the development of the lab scale batch has been successfully completed. Three batches of Remdesivir has been produced with purity 99.72% in lab and obtained 4.73 g in total (1.60 g, 1.55 g, and 1.58 g, respectively). CCSB and CCPC (China Chemical & Pharmaceutical Co., Ltd.) will devote efforts and capabilities to the mass production of Remdesivir as soon as the government calls for instant assistance and supports. CCSB participated the project of Taiwan FDA, Influenza Vaccine Production Process Improvement Project in 2007, and successfully delivered 40kg Tamiflu API on time. Based on the successful experience, CCSB focuses on the production research of Remdesivir to implement CSR when people all over the world have being suffering from the outbreak of COVID-19 since February 2020. CCSB already completed the laboratory process of Remdesivir, proving that CCSB has the ability of development. Remdesivir hasn't been launched officially in the market yet as well as in the originator's clinical stage. CCSB does not plan the launch time of Remdesivir now but will wait for the clinical results. CCSB will fully cooperate and support to government's policies, that won't cause any significant impact on finances and sales.